{"id":245841,"date":"2012-02-15T16:30:51","date_gmt":"2012-02-15T16:30:51","guid":{"rendered":"http:\/\/www.eugenesis.com\/accelpath-llc-provides-business-plan-overview-for-2012\/"},"modified":"2012-02-15T16:30:51","modified_gmt":"2012-02-15T16:30:51","slug":"accelpath-llc-provides-business-plan-overview-for-2012","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/pathology\/accelpath-llc-provides-business-plan-overview-for-2012.php","title":{"rendered":"AccelPath, LLC Provides Business Plan Overview for 2012"},"content":{"rendered":"<p><p class=\"first\">    GAITHERSBURG, MD and WESTWOOD, MA--(Marketwire -02\/15\/12)-    AccelPath, LLC, (\"AccelPath\" or the \"Company\"), a wholly-owned    and operating subsidiary of Technest Holdings, Inc. (OTC.BB:        TCNH.OB -     News), provides its business plan overview for 2012.    AccelPath    was acquired by and took over operating control of Technest    Holdings, Inc. on March 4, 2011.  <\/p>\n<p>    Before 2012, the    Company was developing its core workflow technology. A    portion of this development enabled completing the \"loop\" of    total digital transfer of pathology case information from    histology laboratories to prominent institutional pathologists    and back to referring physicians. These physicians require    accurate, reliable pathology reports to immediately begin    patient treatments. The Company began generating revenues    in 2011 utilizing its newly-developed technology.  <\/p>\n<p>    \"We are pleased that, since AccelPath was formed, we have been    able to achieve our growth and infrastructure development    objectives,\" said Shekhar Wadekar, the Company&#039;s Chief    Executive Officer. \"We believe 2012 should be another exciting    year for the Company, particularly as we expect to implement    our digital pathology workflow solution, continue to expand our    services and increase customer penetration using our successful    and motivated sales force. With our experienced management    team, we expect to meet the milestones we have established for    2012 and beyond.\"  <\/p>\n<p>    About AccelPath  <\/p>\n<p>    AccelPath provides technology solutions that play a key role in    delivering information required for diagnosis of diseases and    other pathologic conditions with and through its associated    institutional pathologists. The medical institutions, with whom    the Company partners, prepare comprehensive diagnostic reports    of a patient&#039;s condition and consult with referring physicians    to help determine the most appropriate treatment. Such    diagnostic reports enable the early detection of disease,    allowing referring physicians to make informed and timely    treatment decisions that improve their patients&#039; health in a    cost-effective manner. The Company seeks out referring    physicians and histology laboratories in need of high-quality    pathology interpretations and manages HIPAA-compliant digital    case delivery and reporting while developing comprehensive    solutions for managing medical information.  <\/p>\n<p>    AccelPath is currently focused on the $14 billion anatomic    pathology market in the US. The Company&#039;s business model builds    upon the expertise of experienced pathologists to provide    seamless, reliable and comprehensive pathology and special test    offerings to referring physicians using conventional and    digital technologies. The Company establishes longstanding    relationships with the referring physicians as a result of    focused delivery of its partner&#039;s diagnostic services,    personalized responses and frequent consultations, and its    proprietary flexible information technology, or IT, solutions    that are customizable to the referring physicians&#039; or    laboratories as well as the pathologists&#039; needs. Such    diagnostic reports often enable the early detection of disease,    allowing referring physicians to make informed and timely    treatment decisions that improve their patients&#039; health in a    cost-effective manner. AccelPath&#039;s IT and communications    platform enables it to efficiently and securely deliver    diagnostic reports to referring physicians. In addition,    AccelPath&#039;s IT platform enables close tracking and monitoring    of medical statistics.  <\/p>\n<p>    Technest focuses on the design, research, development and    integration of three-dimensional imaging devices and systems    primarily in the healthcare industries. The Company also    develops solutions and intelligent surveillance devices and    systems, as well as three-dimensional facial recognition    systems for security and law enforcement agencies.    Historically, the Company&#039;s largest customers have been the    National Institutes of Health and the Department of Defense.    The Company&#039;s solutions leverage several core proprietary    technology platforms, including 3D imaging technologies.  <\/p>\n<p>    Additional Company information may be found on the Internet at:        <a href=\"http:\/\/www.accelpath.com\" rel=\"nofollow\">http:\/\/www.accelpath.com<\/a>.  <\/p>\n<p>    Forward-Looking Statements  <\/p>\n<p>    This press release contains certain \"forward-looking    statements\" relating to the business of the Company, which can    be identified by the use of forward-looking terminology such as    \"may,\" \"will,\" \"expect,\" \"anticipate,\" \"intend,\" \"estimate,\"    \"believe,\" \"project,\" \"continue,\" \"plan,\" \"forecast,\" or other    similar words, or the negative thereof, unless the context    requires otherwise. These statements include, but are not    limited to, statements about the Company&#039;s expected future    performance and achievement of milestones. The results    anticipated by any or all of these forward-looking statements    may not occur. In addition, these statements reflect    management&#039;s current views with respect to future events and    are subject to numerous risks, uncertainties and other factors    that could cause actual results to differ materially from those    set forth in or implied by these forward-looking statements.    Factors that could affect those results include, but are not    limited to, the acceptance of our solutions in the marketplace,    the efforts of our sales force, general economic conditions,    and those described in the Company&#039;s reports on Forms 8-K, 10-Q    and 10-K and proxy statements and information statements, which    have been or will be filed by the Company with the Securities    and Exchange Commission (the \"SEC\"), including without    limitation under the caption \"Risk Factors\" in the Company&#039;s    Annual Report on Form 10-K filed on October 13, 2011. Many of    the factors that will determine the outcome of the subject    matter of this press release are beyond the Company&#039;s ability    to control or predict. The Company undertakes no obligation and    expressly disclaim any obligation, to revise or publicly update    any forward-looking statements, or to make any other    forward-looking statements, whether as a result of new    information, future events or otherwise.  <\/p>\n<\/p>\n<p>The rest is here:<br \/>\n<a target=\"_blank\" href=\"http:\/\/finance.yahoo.com\/news\/accelpath-llc-provides-business-plan-133000449.html\" title=\"AccelPath, LLC Provides Business Plan Overview for 2012\">AccelPath, LLC Provides Business Plan Overview for 2012<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> GAITHERSBURG, MD and WESTWOOD, MA--(Marketwire -02\/15\/12)- AccelPath, LLC, (\"AccelPath\" or the \"Company\"), a wholly-owned and operating subsidiary of Technest Holdings, Inc. (OTC.BB: TCNH.OB - News), provides its business plan overview for 2012 <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/pathology\/accelpath-llc-provides-business-plan-overview-for-2012.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":57,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[577487],"tags":[],"class_list":["post-245841","post","type-post","status-publish","format-standard","hentry","category-pathology"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/245841"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/57"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=245841"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/245841\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=245841"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=245841"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=245841"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}